75847-73-3
Chemical Structure
Enalapril
Synonym(s): MK-421
- CAS No.: 75847-73-3
- Formula:C20H28N2O5
- Molecular Weight:376.45
IUPAC Name: ((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline
InChIKey: GBXSMTUPTTWBMN-XIRDDKMYSA-N
SMILES: O=C(O)[C@H]1N(C([C@H](C)N[C@H](C(OCC)=O)CCC2=CC=CC=C2)=O)CCC1
Biological Activity: Enalapril (MK-421) is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology[1][2][3][4][5][6][7][8][9][10].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enalapril | 99.96% | Enalapril (MK-421) is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Enalapril-d3 | Enalapril-d3 (MK-421-d3) is the deuterated-labeled Enalapril (HY-B0331). Enalapril is an orally active angiotensin-converting enzyme inhibitor. Enalapril blocks the conversion of angiotensin I to angiotensin II, regulates the renin-angiotensin system, reduces preload and afterload, and decreases plasma angiotensin II levels. Enalapril inhibits apoptosis, reduces nitric oxide metabolite levels, stabilizes endothelial cells, enhances endothelial antioxidant defense, scavenges reactive oxygen species (ROS), and alleviates neuronal damage. Enalapril attenuates glutathione depletion, protein/lipid oxidation, tissue damage, and type III collagen immunolabeling in organs of diabetic rats. Enalapril reduces systolic blood pressure and urinary albumin excretion, and delays the progression of diabetic cardiac/renal injury. Enalapril is used in research related to asymptomatic left ventricular dysfunction, congestive heart failure, Alzheimer's disease, diabetes mellitus, acute myocardial infarction, atrial fibrillation, hypertension, cerebral ischemia, chronic heart failure, and single-ventricle physiology. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yusuf S, et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The New England journal of medicine. 1992 Sep 03;327(10):685-91. [Content Brief]
- [2]. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med.
- [3]. Meamar R, et al. Enalapril protects endothelial cells against induced apoptosis in Alzheimer's disease. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2013 Mar;18(Suppl 1):S1-5. [Content Brief]
- [4]. de Cavanagh EM, et al. Enalapril attenuates oxidative stress in diabetic rats. Hypertension (Dallas, Tex. : 1979). 2001 Nov;38(5):1130-6. [Content Brief]
- [5]. Swedberg K, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med. 1992;327(10):678-684.
- [6]. Sicouri S, et al. Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations. Journal of cardiovascular electrophysiology. 2011 Jun;22(6):698-705. [Content Brief]
- [7]. Cunha TA, et al. Effect of stearic acid on enalapril stability and dissolution from multiparticulate solid dosage forms. AAPS PharmSciTech. 2013 Sep;14(3):1150-7. [Content Brief]
- [8]. Ravati A, et al. Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. European journal of pharmacology. 1999 May 28;373(1):21-33. [Content Brief]
- [9]. Packer M, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002 Aug 20;106(8):920-6. [Content Brief]
- [10]. Hsu DT, et al. Enalapril in infants with single ventricle: results of a multicenter randomized trial. Circulation. 2010 Jul 27;122(4):333-40. [Content Brief]
Keywords
